Bempedoic Acid: A New Avenue for the Treatment of Dyslipidemia

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Metabolic Disorders

Background:

• Elevated low-density lipoprotein cholesterol (LDL-C) is a primary risk factor for cardiovascular disease (CVD).
• Statin therapy is the current first-line treatment for dyslipidemia, but some patients do not achieve target LDL-C levels.
• Alternative nonstatin therapies are crucial for managing dyslipidemia in statin-intolerant or statin-resistant patients.

Purpose of the Study:

• To evaluate bempedoic acid as a novel nonstatin therapeutic option for lowering serum cholesterol.
• To assess the efficacy and safety of bempedoic acid in managing dyslipidemia.

Main Methods:

• Bempedoic acid, a prodrug inhibiting adenosine triphosphate-citrate lyase (ACL), was studied at a once-daily 180 mg dose.
• Efficacy was assessed in monotherapy and in combination with statin or ezetimibe.
• Safety and tolerability were evaluated by comparing adverse event rates to placebo.

Main Results:

• Bempedoic acid significantly reduced LDL-C levels when used alone or in combination therapy.
• The drug was generally well-tolerated, with adverse event rates comparable to placebo.
• No significant safety concerns were identified beyond those seen with placebo.

Conclusions:

• Bempedoic acid demonstrates significant LDL-C lowering potential and a favorable safety profile.
• It represents a valuable addition to the nonstatin treatment landscape for dyslipidemia.
• Further clinical trials are needed to confirm its impact on cardiovascular outcomes before widespread adoption as a primary therapy.